Exinalda"TM" - new treatment for fat malabsorption in patients with cystic fibrosis
Exinalda(TM) represents a completely new approach for improving the absorption of lipids and fat soluble vitamins from food. Approximately 90 per cent of the patients suffering from cystic fibrosis have problems digesting fat, caused by pancreatic insufficiency, which can lead to malnutrition, growth failure and increased mortality.
After completing two successful phase II studies and being granted orphan drug status in the EU, Arexis launched the product name Exinalda(TM) for its new treatment of fat malabsorption in patients with cystic fibrosis.
Most read news
Topics
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.